ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

romiplostim

Also written as “Romiplostim”, “AMG 531” and “GNR-069”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.

Drug pageRomiplostim: every studyMany companies study it; this page follows only the 38 they lead. All 90 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 21, 200938 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen252 open or runningphase 4since May 21, 2009Jan 27, 2005Sep 14, 2029phase 3 · NCT07700238
Kyowa Kirinits history only80 open or runningphase 3since Feb 22, 2007Mar 20, 2006none ahead
AO GENERIUMits history only20 open or runningphase 3since Jan 21, 2022Jan 21, 2022none ahead
Geropharmits history only21 open or runningphase 3since Jul 4, 2024Dec 7, 2022Mar 31, 2028phase 3 · NCT06497036
Qilu Pharmaceuticalits history only11 open or runningphase 3since Dec 23, 2025Dec 23, 2025Oct 2029phase 3 · NCT07345000

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jan 27, 2005.

  1. Jan 4, 2007Phase 2 study in Myelodysplastic SyndromesNCT00418665 · 39 enrolled
  2. May 10, 2007No phase study in Myelodysplastic SyndromesNCT00472290 · 72 enrolled
  3. Jul 26, 2007Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT00508820 · 407 enrolled
  4. Aug 9, 2007Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT00515203 · 22 enrolled
  5. Jan 31, 2008Phase 2 study in Myelodysplastic SyndromesNCT00614523 · 250 enrolled
  6. May 21, 2009Phase 4 study in ThrombocytopeniaNCT00907478 · 169 enrolled
  7. Dec 17, 2009Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT01071954 · 66 enrolled · United States, Australia, Canada and more
  8. Jun 10, 2010Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT01143038 · 75 enrolled · United States, Australia, Czechia and more
  9. Sep 29, 2011Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT01444417 · 62 enrolled · United States, Australia, Canada
  10. Oct 1, 2014Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT02279173 · 203 enrolled · United States, Australia, Belgium and more
  11. Oct 12, 20172 phase 3 studiesNCT03362177, NCT03343847
  12. Apr 24, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03937154 · 145 enrolled · United States, Argentina, Brazil and more
  13. Apr 5, 2022Phase 2 study in Anemia, AplasticNCT05323617
  14. Jul 7, 2026Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07700238 · 126 planned · United States, Germany, Hungary and more

Ahead

  1. Sep 14, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07700238

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
avatrombopagruleEisaiphase 425
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 25 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07700238Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Hungary and more3RecruitingSep 14, 2029126
NCT05323617Anemia, Aplastic2WithdrawnFeb 25, 20250
NCT03937154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3Active, not recruitingMar 10, 2026145
NCT03362177Gastrointestinal Neoplasms · United States, Argentina, Austria and more3CompletedJan 25, 2024165
NCT03343847Chemotherapy-induced Thrombocytopenia3WithdrawnJul 17, 20210
NCT02279173Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Belgium and more3CompletedAug 30, 2018203
NCT01444417Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada3CompletedFeb 201562
NCT01143038Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Czechia and more2CompletedSep 20, 201375
NCT01071954Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada and more3CompletedJan 12, 201766
NCT00907478Thrombocytopenia4CompletedJan 9, 2014169
NCT00614523Myelodysplastic Syndromes2CompletedMar 31, 2011250
NCT00515203Purpura, Thrombocytopenic, Idiopathic2CompletedMar 200922
NCT00508820Purpura, Thrombocytopenic, Idiopathic3CompletedJan 1, 2011407
NCT00472290Myelodysplastic Syndromes–CompletedJul 18, 201172
NCT00418665Myelodysplastic Syndromes2CompletedMar 200939
NCT00415532Purpura, Thrombocytopenic, Idiopathic3CompletedNov 7, 2008234
NCT00413283Lung Neoplasms · United States, Austria, Canada and more2CompletedDec 200863
NCT00321711Myelodysplastic Syndromes2CompletedOct 19, 200969
NCT00303472Thrombocytopenia2CompletedMay 200872
NCT00283439Hodgkin Disease2CompletedMay 200839
NCT00117143Purpura, Thrombocytopenic2CompletedJul 19, 200416
NCT00116688Thrombocytopenia3CompletedJan 2010313
NCT00111475Purpura, Thrombocytopenic, Idiopathic2CompletedJun 17, 200445
NCT00102336Thrombocytopenia3CompletedDec 1, 200662
NCT00102323Thrombocytopenia3CompletedSep 1, 200663

How it is read

Names in the registry

  • “Romiplostim”, 22 entries
  • “AMG 531”, 6 entries
  • “GNR-069”, 2 entries
  • “Romiplostim N01”, 1 entry
  • “GP404141”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.